


Macimorelin acetate

Cat. No.:	HY-14820A
CAS No.:	945212-59-9
Molecular Formula:	C ₂₈ H ₃₄ N ₆ O ₅
Molecular Weight:	534.61
Target:	GHSR
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Macimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS) ^{[1][2][3]} .								
IC₅₀ & Target	GHSR ^[1]								
In Vivo	<p>Macimorelin (5 mg/kg, i.p. twice daily for 2 weeks) acetate decreased the number and duration of seizures in IHKA mouse model^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Intrahippocampal kainic acid (IHKA) mouse model^[2]</td> </tr> <tr> <td>Dosage:</td> <td>5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection (i.p.), twice daily for 2 weeks.</td> </tr> <tr> <td>Result:</td> <td>Significantly decreased the number and duration of seizures during the treatment period, but had no antiepileptogenic or disease-modifying effect.</td> </tr> </table>	Animal Model:	Intrahippocampal kainic acid (IHKA) mouse model ^[2]	Dosage:	5 mg/kg	Administration:	Intraperitoneal injection (i.p.), twice daily for 2 weeks.	Result:	Significantly decreased the number and duration of seizures during the treatment period, but had no antiepileptogenic or disease-modifying effect.
Animal Model:	Intrahippocampal kainic acid (IHKA) mouse model ^[2]								
Dosage:	5 mg/kg								
Administration:	Intraperitoneal injection (i.p.), twice daily for 2 weeks.								
Result:	Significantly decreased the number and duration of seizures during the treatment period, but had no antiepileptogenic or disease-modifying effect.								

REFERENCES

- [1]. Jose M Garcia, et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. *J Clin Endocrinol Metab.* 2018 Aug 1;103(8):3083-3093.
- [2]. An Buckinx, et al. Translational potential of the ghrelin receptor agonist macimorelin for seizure suppression in pharmacoresistant epilepsy. *Eur J Neurol.* 2021 Sep;28(9):3100-3112.
- [3]. Ali SA, Garcia JM. Randomized clinical trial of the novel oral ghrelin mimetic macimorelin in the treatment of cancer cachexia: study design and preliminary results. *Endocr Rev.* 2013;34:

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA